Silexion Therapeutics Corp SLXN

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
50/100
Developing

Ranked against 712 peers in Biotechnology

About Silexion Therapeutics Corp

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; … Full SLXN analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 95.0th percentile exceeds peers and WACC, demonstrating superior capital allocation.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.14), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.28), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where SLXN ranks in Biotechnology

Silexion Therapeutics Corp ranks #244 of 713 scored companies in Biotechnology by moat score — the top 34%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
240 DiaMedica Therapeutics Inc. DMAC 50/100 Moderate
241 Biomotion Sciences Warrant SLXNW 50/100 Moderate
242 Bicycle Therapeutics plc BCYC 50/100 Moderate
243 Avidity Biosciences, Inc. RNA 50/100 Developing
244 Silexion Therapeutics Corp SLXN 50/100 Developing
245 Ocular Therapeutix, Inc. OCUL 50/100 Developing
246 Adicet Bio, Inc. ACET 50/100 Developing
247 Cybin Inc. CYBN 50/100 Developing
248 MediWound Ltd. MDWD 49/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How SLXN scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 69 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 19 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding SLXN's moat

What is Silexion Therapeutics Corp's moat score?

Silexion Therapeutics Corp (SLXN) scores 50 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #244 of 713 scored companies in Biotechnology, the top 34%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (69/100) and its weakest is Resilience (19/100).

How does Silexion Therapeutics Corp compare with other Biotechnology companies?

Silexion Therapeutics Corp ranks #244 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Avidity Biosciences, Inc. (RNA) at 50 just above it and Ocular Therapeutix, Inc. (OCUL) at 50 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Silexion Therapeutics Corp scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Silexion Therapeutics Corp?

The Corporate Default template measures 6 defenses, and SLXN scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (69), Resilience (19), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000